BridgeMD
New treatment option for Neoplasms
Official title A Study of JNJ-1761981 in Participants With Solid Tumors
ClinicalTrials.gov ID: NCT07525141
What this study is testing
What is JNJ-1761981?
JNJ-1761981 is an investigational medicine, being studied as a potential treatment for neoplasms.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system [CNS]) who...
- Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology...
- Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1
- Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but...
- A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months...
You likely can't join if
- Active symptomatic disease involvement of the central nervous system
- Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any...
- Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
- Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients
- Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection
The study team makes the final eligibility decision.
Where it's taking place
- Jacksonville, Florida, United States
- Rochester, Minnesota, United States
- The Bronx, New York, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jacksonville, Florida, United States; Rochester, Minnesota, United States; The Bronx, New York, United States; Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.